OBINUTUZUMAB (GA101) VS. RITUXIMAB SIGNIFICANTLY ENHANCES CELL DEATH, ANTIBODY-DEPENDENT CYTOTOXICITY AND IMPROVES OVERALL SURVIVAL AGAINST CD20+ PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL) IN A XENOGRAFT NOD-SCID IL2RGNULL (NSG) MOUSE MODEL: A POTENTIAL TARGETED AGENT IN THE TREATMENT OF PMBL. (October 2022) - Chu, Y.; Awasthi, A.; Lee, S.; Edani, D.; Yin, C.; Hochberg, J.; Shah, T.; Chung, T.; Ayello, J.; van de Ven, C.; Klein, C.; Lee, D.; et al.